Abstract
Medifoxamine is a new monoamine re-uptake inhibiting antidepressant drug. Twelve volunteers received 100 mg by i.v. infusion over 15 min and 500 mg by mouth fasting. The treatments were given 1 week apart in a randomised cross-over design. Venous blood samples (10 ml) were taken at intervals for 24 h for h.p.l.c. measurement of serum medifoxamine. A biexponential decline of serum medifoxamine concentration was observed after intravenous administration in all subjects and similar terminal elimination half-lives were observed following both routes, indicating that oral absorption is not rate-limiting. The absolute bioavailability of oral medifoxamine was 21%.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Johnston A., Woollard R. C. STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods. 1983 May;9(3):193–199. doi: 10.1016/0160-5402(83)90038-4. [DOI] [PubMed] [Google Scholar]
- Saleh S., Johnston A., Chanon M., Turner P. Determination of medifoxamine in plasma and urine by high-performance liquid chromatography. J Chromatogr. 1989 Nov 10;496(1):223–227. doi: 10.1016/s0378-4347(00)82570-0. [DOI] [PubMed] [Google Scholar]